Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Administration of Humanized Anti-CD25 Antibody for Prophylaxis of aGVHD in Patients Older Than 50y Underwent HID-HSCT

NCT05923814 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.

NCT NCT05923814
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05923814 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Administration of Humanized Anti-CD25 Antibody for Prophylaxis of aGVHD in Patients Older Than 50y Underwent HID-HSCT
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China
Phase
Phase 2
Overall status
Unknown status
Start date
July 7, 2023
Completion date
May 7, 2024
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

the effecacy and safety of humanized cd25 antibody in agvhd prophylaxis among elderly patients after hid-hsct